managing-contraception-counseling

# Managing Contraception Counseling

Guides contraception selection using CDC US Medical Eligibility Criteria (US MEC), WHO tiered effectiveness data, and shared decision-making for method selection.

## Why This Skill Exists

Unintended pregnancy accounts for approximately 45% of all pregnancies in the United States. Effective contraception counseling requires matching method efficacy, patient preferences, and medical safety. The CDC US Medical Eligibility Criteria for Contraceptive Use (US MEC) provides a four-category safety classification for every contraceptive method against a comprehensive list of medical conditions. Failure to apply MEC criteria can result in prescribing contraindicated methods (e.g., combined oral contraceptives in a patient with migraine with aura — Category 4, risk of stroke) or unnecessarily withholding safe options from patients with complex medical histories.

This skill structures the counseling session to ensure that method selection is medically appropriate, patient-centered, and properly documented with informed consent.

---

## Checkpoint A: Pre-Draft Intake (Mandatory)

1. **Reproductive goals** — desires pregnancy in < 1 year, 1–5 years, > 5 years, or completed childbearing? (Default: ask patient)
2. **Current and past contraceptive use** — methods tried, reasons for discontinuation, satisfaction? (Default: from history)
3. **Medical conditions** — complete medical/surgical history with focus on MEC-relevant conditions? (Default: from problem list)
4. **Medications** — enzyme-inducing drugs (antiepileptics, rifampin), anticoagulants? (Default: from medication list)
5. **Breastfeeding status** — if postpartum, is patient breastfeeding? Time since delivery? (Default: from postpartum record)
6. **Menstrual history** — LMP, cycle regularity, heavy bleeding, dysmenorrhea? (Default: from history)
7. **Tobacco use** — age and smoking status (critical for combined hormonal methods)? (Default: from social history)
8. **STI risk** — need for dual protection discussed? (Default: assess from sexual history)

### Documents to Request

- Current medication list
- Medical/surgical history summary
- Blood pressure measurement (current visit)
- BMI calculation
- Prior contraceptive use history
- STI screening results (if recent)
- Postpartum/post-abortion records (if applicable)
- Coagulation history (if relevant — personal or family history of VTE)

---

## Step 1: Review Contraceptive Effectiveness Tiers

Present methods in WHO tiered effectiveness framework:

| Tier | Method | Typical-Use Failure Rate (per year) |
|---|---|---|
| **Tier 1 — Most Effective** | Copper IUD (ParaGard) | 0.8% |
| | LNG-IUD (Mirena, Liletta) | 0.1–0.4% |
| | Etonogestrel implant (Nexplanon) | 0.01% |
| | Female sterilization | 0.5% |
| | Vasectomy | 0.15% |
| **Tier 2 — Very Effective** | DMPA injection (Depo-Provera) | 4% |
| | Combined oral contraceptives | 7% |
| | Contraceptive patch (Xulane) | 7% |
| | Vaginal ring (NuvaRing) | 7% |
| **Tier 3 — Moderately Effective** | Male condom | 13% |
| | Female condom | 21% |
| | Diaphragm | 17% |
| | Withdrawal | 20% |
| | Fertility awareness methods | 2–23% |
| **Tier 4 — Least Effective** | Spermicide alone | 21% |
| | Sponge | 14–27% |

Counsel on the difference between perfect-use and typical-use failure rates. Emphasize LARC (IUD, implant) as first-line for most patients per ACOG Committee Opinion No. 642.

---

## Step 2: Apply CDC US Medical Eligibility Criteria (MEC)

The US MEC uses a four-category system:

| Category | Definition | Clinical Action |
|---|---|---|
| **1** | No restriction | Use in any circumstance |
| **2** | Advantages outweigh risks | Generally use — may need follow-up |
| **3** | Risks generally outweigh advantages | Not usually recommended unless no other option |
| **4** | Unacceptable health risk | Do NOT use |

### Critical Category 4 Contraindications (combined hormonal methods):

| Condition | MEC Category for CHCs |
|---|---|
| Migraine with aura (any age) | **4** |
| Current or past VTE | **4** |
| Known thrombogenic mutations (Factor V Leiden, etc.) | **4** |
| Current breast cancer | **4** |
| Smoker age ≥ 35 (≥ 15 cigarettes/day) | **4** |
| < 21 days postpartum (regardless of breastfeeding) | **4** |
| SLE with positive antiphospholipid antibodies | **4** |
| Ischemic heart disease or stroke history | **4** |
| Uncontrolled hypertension (≥ 160/100) | **4** |
| Complicated valvular heart disease | **4** |

### Postpartum MEC Timing

| Time Postpartum | Breastfeeding — CHCs | Not Breastfeeding — CHCs | Progestin-Only | IUD |
|---|---|---|---|---|
| < 21 days | 4 | 4 | 1 | (delay IUD if septic delivery) |
| 21–42 days (no VTE risk) | 3 | 2 | 1 | 1 |
| 21–42 days (with VTE risk) | 3 | 3 | 1 | 1 |
| > 42 days | 2 | 1 | 1 | 1 |

Document the MEC category for the selected method and each condition evaluated.

---

## Step 3: Method-Specific Counseling

For each method discussed, document:

1. **Mechanism of action** — hormonal suppression, barrier, copper toxicity, etc.
2. **Administration** — insertion procedure, prescription, self-administered
3. **Expected side effects** — bleeding pattern changes, hormonal effects
4. **Warning signs requiring return** — severe headache, leg swelling, chest pain for CHCs; expulsion signs for IUD; implant migration concerns
5. **Duration of use / replacement schedule** — Mirena (8 years), Liletta (8 years), ParaGard (10 years), Nexplanon (3 years), DMPA (every 12 weeks)
6. **Return to fertility** — immediate for most methods; DMPA may delay 10–18 months
7. **STI protection** — remind that only condoms protect against STIs; recommend dual use

---

## Step 4: Special Populations

### Adolescents
- LARC is first-line per ACOG and AAP
- Confidentiality considerations per state law
- Emergency contraception education mandatory

### Immediate Postpartum / Post-Abortion
- IUD and implant can be placed immediately (within 10 minutes of placental delivery for IUD; before discharge for implant)
- Immediate post-placental IUD has slightly higher expulsion rate (10–15%) but dramatically improves access
- Document timing of placement relative to delivery

### Perimenopause
- Continue contraception until 12 months of amenorrhea (if age > 50) or 24 months (if age < 50)
- Switch from CHCs to progestin-only or non-hormonal methods after age 50–55 when VTE risk increases
- FSH is unreliable for confirming menopause while on hormonal contraception

---

## Step 5: Emergency Contraception

Document knowledge of and access to emergency contraception:

| Method | Timing | Effectiveness |
|---|---|---|
| Levonorgestrel (Plan B) | Up to 72 hours (some efficacy to 120 hours) | 89% (decreases with delay) |
| Ulipristal acetate (ella) | Up to 120 hours | 85% (no decrease in efficacy window) |
| Copper IUD | Up to 120 hours (most effective EC available) | > 99% |

Note: levonorgestrel may be less effective in patients with BMI > 25; ulipristal acetate may be less effective with BMI > 35; copper IUD is effective regardless of weight.

---

## Checkpoint B: Post-Draft Alignment (Mandatory)

1. **Are all relevant medical conditions screened** against the US MEC criteria for the selected method?
2. **Is the method's MEC category documented** for each pertinent condition?
3. **Is typical-use failure rate communicated** (not just perfect-use)?
4. **Is informed consent documented** — risks, benefits, alternatives, and patient questions addressed?
5. **Is the follow-up plan stated** — return visit for IUD string check, BP recheck for CHC start, or injection schedule for DMPA?

---

## Quality Audit

- [ ] Reproductive goals documented
- [ ] Medical conditions screened against US MEC criteria
- [ ] MEC category for selected method documented for all relevant conditions
- [ ] Category 4 contraindications excluded before prescribing combined hormonal methods
- [ ] Blood pressure documented (required before CHC initiation)
- [ ] BMI documented
- [ ] Smoking status and age documented (relevant for CHC eligibility)
- [ ] Method effectiveness communicated with typical-use failure rate
- [ ] Side effects and warning signs reviewed with patient
- [ ] STI protection discussed (dual-method use)
- [ ] Emergency contraception discussed and/or prescribed
- [ ] Follow-up plan documented
- [ ] Informed consent documented
- [ ] LARC offered as first-line option per ACOG recommendation

---

## Guidelines

1. **Always check MEC before prescribing** — never prescribe combined hormonal contraception without evaluating Category 3 and 4 conditions.
2. **Offer LARC first** — per ACOG, IUDs and implants should be offered as first-line due to superior effectiveness and continuation rates.
3. **Document the "no contraindication" assessment** — record that BP was checked, smoking status assessed, and migraine history reviewed before starting CHCs.
4. **Address the top reason for discontinuation** — unacceptable bleeding patterns are the #1 reason patients stop contraception; counsel proactively about expected changes.
5. **Quick-start when appropriate** — per CDC Selected Practice Recommendations, most methods can be started on the same day as the visit with reasonable exclusion of pregnancy (no need to wait for next menses).
6. **Use shared decision-making** — present options within tiers, answer questions, and let the patient choose; avoid coercive language about any method.
7. **Document refusal with respect** — if a patient declines LARC or any recommended method, document the discussion and the patient's preference without judgment.
8. **Review emergency contraception** — all patients should leave with knowledge of EC options regardless of their chosen method.